Wlodarska I, De Wolf-Peeters C, Falini B, Verhoef G, Morris S W, Hagemeijer A, Van den Berghe H
Center for Human Genetics, Department of Pathology, Hematology, K.U. Leuven, Leuven, Belgium.
Blood. 1998 Oct 15;92(8):2688-95.
Recently, a distinctive entity characterized by expression of the anaplastic lymphoma kinase (ALK) protein [most frequently due to the t(2;5)(p23;q35)-associated NPM-ALK fusion] has emerged within the heterogenous group of non-Hodgkin's lymphomas (NHL) classified as anaplastic large-cell lymphoma (ALCL). Sporadic variant 2p23/ALK abnormalities identified in ALK-positive ALCL indicate that genes other than NPM may also be involved in the deregulation of ALK and lymphomagenesis. We report here three cases with an inv(2)(p23q35) detected by fluorescence in situ hybridization (FISH) in young male patients with ALK-positive ALCL. In contrast to ALCL cases with the classical t(2;5)(p23;q35) that usually show both cytoplasmic and nuclear or predominantly nuclear alone localization of the NPM-ALK chimeric product, in all three cases with an inv(2)(p23q35) the ALK protein accumulated in the cytoplasm only, supporting the previous assumption that the oncogenic potential of ALK may not be dependent on its nuclear localization. As the first step to identify the ALK partner gene involved in the inv(2)(p23q35), we performed extensive FISH studies and demonstrated that the 2q35 breakpoint occurred within the 1,750-kb region contained within the 914E7 YAC. Moreover, a striking association of the inv(2)(p23q35) with a secondary chromosomal change, viz, ider(2)(q10)inv(2)(p23q35), carrying two additional copies of the putative ALK-related fusion gene, was found in all three patients, suggesting that, in contrast to the standard t(2;5)/NPM-ALK fusion, multiple copies of the putative 2q35-ALK chimeric gene may be required for efficient tumor development. In summary, we demonstrate that the inv(2)(p23q35), a variant of the t(2;5)(p23;q35), is a recurrent chromosomal abnormality in ALK-positive ALCL, the further characterization of which should provide new insight into the pathogenesis of these lymphomas.
最近,在分类为间变性大细胞淋巴瘤(ALCL)的非霍奇金淋巴瘤(NHL)异质性组中,出现了一种以间变性淋巴瘤激酶(ALK)蛋白表达为特征的独特实体[最常见于t(2;5)(p23;q35)相关的NPM-ALK融合]。在ALK阳性ALCL中发现的散发性2p23/ALK变异异常表明,除NPM外的其他基因也可能参与ALK的失调和淋巴瘤发生。我们在此报告3例通过荧光原位杂交(FISH)在ALK阳性ALCL年轻男性患者中检测到inv(2)(p23q35)的病例。与通常显示NPM-ALK嵌合产物在细胞质和细胞核中或仅主要在细胞核中定位的经典t(2;5)(p23;q35)的ALCL病例不同,在所有3例inv(2)(p23q35)病例中,ALK蛋白仅在细胞质中积累,支持了先前的假设,即ALK的致癌潜力可能不依赖于其核定位。作为鉴定参与inv(2)(p23q35)的ALK伙伴基因的第一步,我们进行了广泛的FISH研究,并证明2q35断点发生在914E7 YAC所含的1750 kb区域内。此外,在所有3例患者中均发现inv(2)(p23q35)与继发性染色体改变即ider(2)(q10)inv(2)(p23q35)显著相关,并携带两个额外拷贝的假定ALK相关融合基因,这表明与标准t(2;5)/NPM-ALK融合不同,可能需要多个拷贝的假定2q35-ALK嵌合基因才能实现有效的肿瘤发展。总之,我们证明inv(2)(p23q35)作为t(2;5)(p23;q35)的一种变异,是ALK阳性ALCL中一种反复出现的染色体异常,对其进一步的特征分析应能为这些淋巴瘤的发病机制提供新的见解。